Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside

Life Science

Lilly Accelerates M&A Push, Targeting Scientific “White Spaces”

Life Science

STAAR Surgical Announces $50 Million Buyback Plan, Stock Soars More Than 7% on Friday

Life Science

ByteDance’s Anew Labs Emerges With $1.5B Valuation, Stirring New Questions Over AI Drug Discovery

Life Science

Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path

Life Science

BMY vs. JNJ: Low Valuation and High Yield or High Profit and Steady Growth?

Life Science

AI Finds New Clues for Gene Editing, but It Is Still Far from a “New CRISPR”

Life Science

Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk?

Life Science

Iambic Therapeutics Files for U.S. IPO, Adding Another AI Drug-Discovery Startup to Nasdaq Pipeline

Life Science, Technology

Johnson & Johnson Accelerates Divestiture of DePuy Synthes, Investors Optimistic About Streamlined Strategy

Life Science

Eli Lilly Stock Trails the Market, and Its Growth Story Faces a Test Under a High Valuation

Life Science

Abbott vs. Intuitive Surgical: Two Healthcare Titans on Diverging Growth Curves

Life Science, Technology

Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge

Life Science

US Weighs Allowing Most Pharma Licensing Deals With China, Sources Say

Life Science

Johnson & Johnson vs. Kenvue, Which Is Better Suited for a Defensive Dividend Portfolio?

Life Science